did not lead to complete reversal of the anticowpox virus activity of ribavirin. This suggests that other modes of virus inhibition also appear to contribute to the anti-orthopoxvirus activity of ribavirin. Biological differences in mode of action and immunosuppressive potential between ribavirin and MPA may account for why the former compound is active against orthopoxvirus infections in animals and the latter inhibitor is not.
The treatment of orthopoxvirus infections may be important for military and civilian defence purposes (Breman & Henderson, 1998; Orent, 1998) , to combat emerging infections such as those caused by monkeypox virus (Heymann et al., 1998) , and to halt the progression of poxvirus infections in immunocompromised individuals (Kesson et al., 1997) . Molluscum contagiosum, caused by another poxvirus, is a problematic skin infection in AIDS patients (Munoz-Perez et al., 1998 ). An approved treatment for all of these conditions will be important.
Historically, marboran® was used to treat smallpox virus infections (Heiner et al., 1971) . From the responses of patients to treatment it was concluded that the drug was largely ineffective. (S)-9-(3-Hydroxy-2-phosphony(meth oxypropyl)adenine (HPMPA) and cidofovir (HPMPC) have been used successfully in experimental mouse models of poxvirus infections (De Clercq et al., 1989; Neyts & De Clercq, 1993) . HPMPC is effective in the treatment of molluscum contagiosum (poxvirus) infections in AIDS patients (Meadows et al., 1997; Davies et al., 1999; Toro et al., 2000) . In addition, the drug is very effective in mouse models of cowpox (Bray et al., 2000; Smee et al., 2000a) and vaccinia (Smee et al., 2001a, b) virus infections. Ribavirin is reported to be active in a vaccinia tail lesion infection model (De Clercq et al., 1976) and against cowpox virus (Smee et al., 2000b) in mice. When combined with immune globulin, ribavirin is effective in treating a vaccinia infection in an immunocompromised man (Kesson et al., 1997) . A third compound, 7-(1,3-dihydroxy-2propoxymethyl)purine, is effective against vaccinia virus infections in mice (Neyts & De Clercq, 2001) .
In the course of our ongoing poxvirus studies we discovered that mycophenolic acid (MPA) was a potent inhibitor of these viruses in cell culture. Since an orally bioavailable prodrug form of the compound (mycophenolate mofetil) is already a licensed drug for transplantation rejection Two inhibitors of cellular inosine monophosphate dehydrogenase, mycophenolic acid (MPA) and ribavirin, were evaluated for inhibitory activity against orthopoxviruses. Unrelated antipoxvirus agents tested for comparison included 6-azauridine, cidofovir (HPMPC) and cyclic HPMPC. MPA inhibited camelpox, cowpox, monkeypox and vaccinia viruses by 50% in plaque reduction assays at 0.2-3 µM in African green monkey kidney (Vero 76) and mouse 3T3 cells. Ribavirin was considerably more active in 3T3 cells (50% inhibition at 2-12 µM) than in Vero 76 cells (inhibitory at 30-250 µM) against these viruses. In cytotoxicity assays, MPA and ribavirin were more toxic to replicating cells than to stationary cell monolayers, with greater toxicity seen in 3T3 than in Vero 76 cells. The superior antiviral potency and increased toxicity of ribavirin in 3T3 cells was related to greater accumulation of mono-, di-and Introduction (Allison & Eugui, 1994; Hood & Zarembski, 1997) , MPA represented a viable candidate for further exploration of its antipoxvirus potential.
MPA inhibits cellular inosine monophosphate dehydrogenase (IMPDH), without requiring intracellular metabolism (Ransom, 1995) . Ribavirin monophosphate is the active intracellular form of ribavirin that inhibits IMPDH (Streeter et al., 1973) . As a result of inhibition of IMPDH by either compound, intracellular pools of guanosine triphosphate (GTP) and 2′-deoxyguanosine triphosphate (dGTP) are decreased, causing inhibition of viral and cellular RNA, DNA and protein synthesis (Streeter et al., 1973; Lowe et al., 1977) . Vaccinia virus DNA and protein syntheses are inhibited by ribavirin (Katz et al., 1976) . In addition to the effects caused by inhibition of IMPDH, ribavirin triphosphate, the major intracellular metabolite of ribavirin (Miller et al., 1977; Smee & Matthews, 1985) , inhibits the capping of vaccinia virus mRNA (Goswami et al., 1979) .
In this report we compared the antipoxvirus activities of MPA, ribavirin and other inhibitors in cell culture. Mode of action studies with MPA and ribavirin implicated IMPDH inhibition as the important cellular target leading to antiviral activity. Ribavirin metabolism studies were conducted to explain differences in the antiviral potency of the compound observed in two cell lines.
Materials and methods

Antiviral compounds
Mycophenolic acid, 6-azauridine (Smee et al., 1987) and guanosine were purchased from Sigma Chemical Co., St. Louis, Mo., USA. Ribavirin was purchased from ICN Pharmaceuticals, Costa Mesa, Calif., USA. [ 3 H]ribavirin was obtained from Moravek Biochemicals, Brea, Calif., USA. HPMPC and cyclic HPMPC (a prodrug form of cidofovir; Bischofberger et al., 1994) were kindly provided by Norbert Bischofberger, Gilead Sciences, Foster City, Calif., USA.
Viruses and cells
Camelpox (Somalia strain), cowpox (Brighton strain), monkeypox (Zaire strain) and vaccinia (Copenhagen strain) viruses were obtained from Joseph Esposito, Centers for Disease Control and Prevention, Atlanta, Ga., USA. The viruses were propagated in African green monkey kidney (Vero 76) cells. Vero 76 and Balb/3T3 clone A31 cells (hereafter referred to as 3T3 cells) used in virus experiments were obtained from the American Type Culture Collection, Rockville, Md., USA. A second line of African green monkey kidney (MA-104) cells were purchased from BioWhittaker, Walkersville, Md., USA, and used in selected studies. All the cells were cultured in Dulbecco's high glucose medium containing 10% fetal bovine serum. The serum concentration was reduced to 2% for antiviral assays. Low cell-culture passage (three times passaged from originally obtained stocks) of wild-type viruses were used for studies.
Antiviral experiments
Sensitivities of the poxviruses to the selected antiviral compounds were determined by plaque reduction assays in 6-well plates containing confluent monolayers of Vero 76 and 3T3 cells. Plates of cells were infected with about 100 plaque forming units (pfu) of virus per well, virus was adsorbed for 1.5-2 h, then twofold dilutions of drug were applied. Incubation times varied with each virus as follows: vaccinia, 3 days; cowpox, 4 days; monkeypox, 6 days; and camelpox, 7 days. Plaque sizes were about 3 mm in diameter at these times for vaccinia, cowpox and monkeypox, whereas camelpox produced 1 mm plaques. Cells were fixed and stained in 3% buffered formalin/0.1% crystal violet for 15 min. Plaques were counted with the aid of a hand-held magnifying lens (6-inch diameter). This was especially beneficial for observing and counting tiny plaques that might otherwise have been overlooked. The concentration of compound causing a 50% reduction in virus plaque numbers was determined by plotting concentration versus percentage of control on semilog graph paper.
Virus yield assays were conducted in 12-well plates of cells infected with cowpox or monkeypox viruses at about 100 pfu per well. After virus adsorption (1.5-2 h) the cells were fed maintenance medium with or without drug. Each day (or as indicated in the figure legends) a portion of the infected cells were frozen, thawed and sonicated for 30 s. Subsequently, the medium (representing both intracellular and extracellular virus produced during the infection) was titrated by plaque assay on new monolayers of Vero 76 cells in 6-well plates. After 4 or 6 days, the cells were fixed, stained and plaques counted.
Cytotoxicity determinations
Two types of assay were performed, those done in monolayer cell cultures and others performed using actively dividing cells. For monolayer cell assays, confluent cell cultures in 96-well microplates were exposed to compounds at varying half-log 10 dilutions for 7 days. The time of incubation coincided with the longest incubation time used in antiviral assays (that is, for camelpox virus). Cell culture medium for these studies contained 2% serum. At the end of the incubation period the plates of Vero 76 cells received a 0.11% final concentration of neutral red for 2 h at 37°C. Then the plates were rinsed twice with PBS and the dye in each well was solubilized with 50% Sörensen's citrate buffer/50% ethanol. Plates were read for optical density at 540/405 nm dual wavelengths. The 3T3 cells had to be treated differently because the cells were very fragile in the wells and came off with rinsing. Thus, an alternative procedure requiring no rinsing was used. After incubation, the contents of each well was aspirated off. Then 0.02% sodium dodecyl sulphate (SDS) made up in SSC buffer (15 mM trisodium citrate in normal saline at pH 7.0) was added to each well. After 1 h, an equal part of 1 µM bisbenzimide (Hoechst 33258 from Sigma Chemical Co., St. Louis, Mo., USA) in SDS/SSC was added. The plates were read with a fluorometer at 355 exitation/455 emission nm. Both the neutral red and Hoechst 33258 procedures have been used by others to estimate relative cell numbers (Borenfreund et al., 1988; Papadimitriou & Lelkes, 1993) . The concentration of compound causing a 50% reduction in optical density or fluorescence (IC 50 value) was determined by plotting concentration versus percentage of control on semilog graph paper.
The actively dividing cell assay consisted of seeding 24well microplates with approximately 1×10 4 cells/well and letting them attach overnight. Then compounds were added at varying half-log 10 dilutions. After 3 days of incubation the cells were subjected to neutral red as described above. The eluted dye from each well was transferred to a 96-well plate in order to be read optically for determination of IC 50 values. The dividing cell assay was run for a shorter period of time than the monolayer assay so that the cells did not grow to confluency during the experiment. This type of assay is much more sensitive for determining the toxicity of compounds than the monolayer assay.
Quantitation of intracellular metabolites of ribavirin
The extent of metabolism of ribavirin to mono-(RMP), di-(RDP) and triphosphate (RTP) derivatives was studied in three cell lines. A constant amount of [ 3 H]ribavirin (10 µCi/ml) was combined with non-radioactive ribavirin at 10, 30, 100 or 300 µM in the same cell culture medium used in plaque reduction assays. Because specific radioactivity decreased with increasing drug concentration, this was later taken into account in performing mathematical calculations with the resulting data. Confluent monolayers of uninfected cells in T-25 flasks were exposed to the ribavirin concentrations indicated above for 8 h. This was shown previously to be the time when plateau levels of ribavirin metabolites were reached inside MA-104 cells (Smee & Matthews, 1985) . Untreated control flasks were maintained in parallel in order to determine cell numbers (by trypsinization and subsequent counting with a haemacytometer). After the incubation period, the radioactive medium was removed and part was saved to determine counts per minute (cpm) of radioactivity per pmol of drug. To each flask 0.6 ml of 3.5% perchloric acid was added, after which the flasks were stored at 4°C for 5 min. The samples were then neutralized with 10 N KOH containing 1 M imidazole. The resulting fluids were collected and stored at -70°C until analysis. Separation of ribavirin metabolites was done by a modification of the high pressure liquid chromatography (HPLC) method previously described (Smee & Matthews, 1985) . Briefly, samples were analysed using an HPLC system (Varian Chromatography Systems, Woburn, Mass., USA) fitted with a 10×250 mm strong anion exchange (SAX) column (Whatman, Clifton, NJ, USA) using a linear gradient of 10 mM-1 M ammonium phosphate buffer, pH 3.5 and a 1 ml/min flow rate. The 10 mM buffer was run for the first 5 min, followed by the gradient from 5 to 25 min. Then, the 1 M buffer was run for an additional 15 min prior to re-equilibration at the low salt concentration in preparation for the next analysis. Quantitation of radioactive RMP, RDP, and RTP was made using a β-Ram flow-through radioactivity detector (IN/US Systems, Tampa, Fla., USA). Calculations of intracellular metabolites of ribavirin were based on pmol of compound per 10 6 cells.
Effects of drugs on intracellular GTP pools
Inhibition of cellular IMPDH results in reduction in the intracellular guanosine triphosphate (GTP) pool (Lowe et al., 1977) . In order to quantify this effect and correlate it to antiviral activities, 6-well plates of uninfected monolayers of Vero 76 and 3T3 cells were exposed to ribavirin or MPA for the same periods of time, at the same drug concentrations and using the same cell culture medium as those used for virus yield reduction experiments. At the end of the 3-day incubation period, the medium was removed and nucleotides released from cells using perchloric acid followed by KOH/imidazole as described above. GTP in cell extracts was analysed by HPLC using a Whatman SAX column under isocratic conditions. Buffer was 0.65 M ammonium phosphate, pH 3.5 at a flow rate of 2 ml/min. Peak areas from optical density (260 nm) plots were obtained, and results of drug treated samples were converted to percentages of untreated control cell cultures (arbitrarily set at 100%). We did not convert GTP peak areas into pmol of GTP per 10 6 cells, although others have reported the GTP pool size in a mouse lymphoma cell line (L5178y) to be 5.3 pmol/10 6 cells (Müller et al., 1977) . GTP studies were conducted using stationary cell cultures but not with actively dividing cells, since the results from such experiments would not be correlated back to antiviral activity (all virus experiments were performed with cell monolayers).
Results
Antiviral activities of five compounds were determined in plaque reduction assays performed in 3T3 and in Vero 76 cells (Table 1) . MPA was the most potent of the agents tested, inhibiting replication of four poxviruses between 0.2-1.3 µM in 3T3 cells or 0.8-3.0 µM in Vero 76 cells. Ribavirin, HPMPC and cyclic HPMPC showed differential effects between the two cell lines, with plaque inhibition at lower concentrations in 3T3 cells. 6-azauridine was approximately as potent in Vero 76 cells as it was in 3T3 cells against the viruses, with exception of cowpox virus. Overall, the compounds showed relatively similar potencies in 3T3 cells, but only MPA and 6-azauridine were highly active in Vero 76 cells.
The toxicities of the five antiviral compounds were determined both in stationary cell monolayer cultures and in rapidly proliferating cells (Table 1) . MPA, ribavirin and 6-azauridine was more toxic to replicating cells than to cell monolayers. The opposite was true for HPMPC and cyclic HPMPC, which possibly suggests cumulative toxicity, since in the monolayer assay the cells were incubated with the drug 4 days longer than in the replicating cell assay. MPA and 6-azauridine were inhibitory to rapidly proliferating 3T3 and Vero 76 cells at low concentrations. Ribavirin was much more inhibitory to the proliferation of 3T3 cells than to Vero 76 cells. Compounds with the greatest selectivity indices (based on the data derived from rapidly proliferating cells) were HPMPC and cyclic HPMPC, whereas MPA and 6-azauridine inhibited cell proliferation at nearly the same concentrations as those affecting virus replication. Ribavirin showed only a moderate degree of viral selectivity compared with HPMPC and cyclic HPMPC.
A follow-up antiviral experiment was performed to determine how long virus replication would be suppressed in cells following removal of MPA or ribavirin from the cell culture medium (Figure 1 ). Concentrations of 32 µM MPA and 1 mM ribavirin were approximately equally inhibitory to cowpox virus in Vero 76 cells and were selected. After 1 day in culture, 100-fold more virus was present in placebotreated cells compared with drug-treated cells. No more than a 10-fold increase in virus titre occurred as long as drugs were present. However, in cultures treated for only one day, virus titres rose quickly thereafter to equal the control virus titre by day 4. Thus, removal of either drug from the medium led to rapid rebound in virus titre production. Both MPA and ribavirin showed the same rates of virus rebound following drug removal.
The effect of drug treatment on GTP suppression in cells was compared with reductions in poxvirus yields (Figure 2 ). Concentrations of MPA and ribavirin that Infected Vero 76 cells were exposed to 32 µM mycophenolic acid (MPA) or 1 mM ribavirin. , untreated; , MPA treatment for 1 day; , MPA treatment for 4 days; Í , ribavirin treatment for 1 day; ▲, ribavirin treatment for 4 days.
caused weak to potent inhibition of cowpox and monkeypox viruses were selected. Untreated confluent monolayer cultures of Vero 76 cells had essentially the same intracellular GTP concentration as 3T3 cells, based on GTP peak area per 10 6 cells. Thus, effects of compound on GTP pools and on virus production in the two cell lines should correlate to the behaviour (that is, uptake and metabolism) of the compound rather than whether there were differences between 3T3 and Vero 76 cell GTP levels in untreated cells. MPA showed similar degrees of GTP suppressive activity in both 3T3 and Vero 76 cells (Figure 2a ). Taking into account that virus production was higher in Vero 76 cells than in 3T3 cells, the degrees of suppression of cowpox and monkeypox viruses in the two cell lines by MPA were similar. The shapes of the virus inhibition curves paralleled the GTP suppression curves. Ribavirin was much more potent in 3T3 than in Vero 76 cells, both as a suppressor of GTP pools and as an antiviral agent (Figure 2b) . The shapes of the GTP suppression curves were nearly parallel for the two cell lines, as were the virus inhibition curves, indicating a positive correlation between virus inhibition and GTP suppression in either type of cell. Restoration of the intracellular GTP pool in drug-treated cultures can be accomplished by treatment of cells with extracellular guanosine (Lowe et al., 1977) , causing a reversal of antiviral action (Streeter et al., 1973; Smee et al., 1981) . In 3T3 cells treated with both MPA and guanosine, the extent of virus inhibition was increasingly reduced as the extracellular guanosine concentration increased ( Figure  3a) . At 128 and 256 µM guanosine concentrations, MPA activity was completely or nearly completely reversed. Guanosine alone at the higher concentrations caused some inhibition of virus yield. Treatment of cultures with ribavirin and guanosine led to an incomplete reversal of antiviral activity at the higher guanosine concentrations (Figure 3b ). Partial reversal of antiviral activity was seen at the 32 µM guanosine concentration (lower concentrations were not tested). The intracellular GTP pools ranged from 94 to 135% of the untreated control at 128 µM extracellular guanosine concentration, and from 185 to 198% of control at 256 µM extracellular guanosine level in cells treated either with MPA (4 and 16 µM) or ribavirin (16 and 64 µM). The comparative results for MPA and ribavirin suggest that other modes of action of ribavirin, such as the inhibition of capping of poxvirus mRNA by ribavirin triphosphate (Goswami et al., 1979) , may also play a role in the activity of the drug besides the suppression of the GTP pool.
The data above indicate that higher concentrations of ribavirin are required to suppress GTP levels in Vero 76 cells than in 3T3 cells, but do not explain why. The inhibition of IMPDH is caused by RMP (Streeter et al., 1973) , suggesting that phosphorylated derivatives (importantly RMP) may build up to higher levels in 3T3 than in Vero 76 cells, resulting in more potent virus inhibition in 3T3 cells. To test this hypothesis, uninfected cells were treated with [ 3 H]ribavirin for 8 h then intracellular metabolites were quantified (Table 2 ). For each cell line used, the amounts of intracellular ribavirin, RMP, RDP and RTP were dose dependent on the extracellular concentration. 3T3 cells had 10-to 18-fold higher concentrations of RMP compared with Vero 76 cells. Intracellular ribavirin, RDP and RTP levels were also higher in 3T3 cells compared with Vero 76 cells. A second African green monkey cell line (MA-104) was run as a control, the extent of phosphorylation in these cells being comparable to the previously published results (Smee & Matthews, 1985) . Vero 76 cells were least active in phosphorylating ribavirin. The difference in the extent of phosphorylation of ribavirin between 3T3 and Vero 76 cells was roughly the same as the potency differences for inhibition of camelpox, cowpox and monkeypox viruses in these cells. For unexplained reasons, there was only a threefold difference in the antiviral activity of ribavirin against vaccinia virus in 3T3 versus Vero 76 cells (see Table 1 ). Thus, for vaccinia virus other factors may also affect inhibition of the virus in these cells.
Discussion
Recent interest has been shown in MPA as an antiviral agent, particularly as a potentiator of the antiherpesvirus activities of acyclovir and ganciclovir . Prior to this report, the potential of MPA as an antipoxvirus agent has not been well studied. The antiviral potencies of MPA and 6-azauridine were found to not vary more than fourfold between Vero 76 to 3T3 cells, but the toxicity of MPA to proliferating 3T3 cells was fivefold greater. The antiviral potencies and cytotoxicities of ribavirin, HPMPC and cyclic HPMPC were greater in 3T3 cells than in Vero 76 cells. The more potent effects of ribavirin in 3T3 cells was shown to be due to a much greater accumulation of ribavirin, RMP, RDP and RTP. HPMPC was also phosphorylated to a greater extent in 3T3 than in Vero 76 cells (data not shown). Interestingly, in another African green monkey kidney cell line (MA-104) related to Vero 76, the extent of phosphorylation of ribavirin was also much greater than in Vero 76 cells. It would have been interesting to compare the extent of uptake of MPA into 3T3 and Vero 76 cells, but radioactive drug was not commercially available.
The extent of uptake of ribavirin into cells was dependent on the extracellular concentration. It was initially thought that the amount of ribavirin inside and outside 3T3 and Vero 76 would be essentially the same after equilibration. This was not the case, however, since the amount of ribavirin taken into 3T3 cells was about 4.3-fold greater than the amount in Vero 76 cells. We recently reported that carbocyclic 3-deazaadenosine was transported into 3T3 cells to a greater extent than into Vero 76 cells, and a greater extent of phosphorylation occurred in 3T3 cells (Smee et al., 2001c) .
Inhibitory effects of MPA and ribavirin on cowpox virus replication in Vero 76 cells were shown to be fully reversible following removal of either agent from the extracellular medium. Drug had to be continuously present in order to suppress virus titre production. It was previously demonstrated that the metabolites of ribavirin undergo rapid catabolism following drug removal (Smee & Matthews, 1985) . Since MPA undergoes no metabolism in cells, it is most likely excreted rapidly from cells following removal of the drug from the extracellular medium. Treatment of animals or humans with either substance would logically require frequent administration (predicated upon biological half-life of the compounds in vivo), as was done using ribavirin to protect mice against lethal cowpox virus infections (Smee et al., 2000a) .
The extent of ribavirin phosphorylation is dependent on cell type, which may explain why the drug is only mildly immunosuppressive in animals ( Jolley & Hinshaw, 1980) , assuming that cells of the lymphoid system do not phosphorylate ribavirin as well as other cells in the body. In support of this hypothesis, we found that ribavirin is poorly metabolized in the lymphoblastoid Daudi cell line (unpublished) . Giving a weakly immunosuppressive antiviral agent would benefit the animal in mounting an immune response against orthopoxvirus infections. On the other hand, ribavirin may not be phosphorylated extensively in certain cells of the body where the virus replicates, which would result in a weaker antiviral effect. MPA does not require phosphorylation or other metabolism to exert its action (Ransom, 1995) , allowing it to be less variable in inhibition of IMPDH among varying cell types (and more immunosuppressive than ribavirin in animals). Each of the three metabolites of ribavirin has shown biological activity resulting in inhibition of certain RNA or DNA viruses. RMP inhibits cellular IMPDH, causing decreased intracellular GTP and dGTP levels (Streeter et al., 1973) . This in turn causes suppression in cellular DNA, mRNA and protein synthesis (Lowe et al., 1977; Müller et al., 1977; Smee et al., 1982) . Rotavirus polypeptide synthesis was shown to be inhibited to a much greater extent than cellular protein synthesis (Smee et al., 1982) in monolayer cell cultures. RDP was inhibitory to vesicular stomatitis virus RNA polymerase (Toltzis et al., 1988) . RTP caused inhibition of influenza virus RNA polymerase (Eriksson et al., 1977) . RTP was also shown to inhibit the capping of vaccinia virus mRNA (Goswami et al., 1979) , which would lead to an inhibition of viral protein synthesis. Suppression of intracellular dGTP levels presumably would slow down poxvirus DNA synthesis.
Extracellular guanosine treatment has been shown to reverse the antiviral activity of ribavirin against viruses other than orthopoxviruses (Streeter et al., 1973; Smee et al., 1981) and to reverse cytotoxicity (Müller et al., 1977) . Because ribavirin activity against cowpox virus was not fully reversible by extracellular guanosine treatment, this may support the role of other modes of action of ribavirin against poxviruses besides IMPDH inhibition. In a related study, Robins et al. (1986) reported achieving only a partial reversal of ribavirin inhibition of vaccinia virus replication in Vero 76 cells by extracellular guanosine treatment. The extensive comparisons presented here that correlate intracellular GTP pool levels with degrees of virus inhibition under a variety of conditions, support the role of IMPDH inhibition in antipoxvirus activity, but do not exclude other inhibitory modes of action in the case of ribavirin.
We have evaluated MPA for efficacy against cowpox virus respiratory infections in mice using a variety of treatment regimens, and found it to be completely inactive in preventing death or in extending the mean day of death at doses of 10, 30 and 100 mg/kg per day (unpublished data). At the 100 mg/kg per day dose given for 7 consecutive days, the mice failed to gain weight and died sooner than counterpart placebo control animals, suggesting that the maximum tolerated dose was used. The failure of MPA to be effective in mice may partly be due to its rapid metabolism to an inactive glucuronide derivative (Sweeney et al., 1972) . Our suspicion is that the immunosuppressive effects of MPA (Hood & Zarembski, 1997 ) also contribute to its inefficacy against cowpox virus infections in vivo. Immunosuppressed animals are much more susceptible to poxvirus infections than normal animals (Neyts & De Clercq, 1993) , because the immune system is essential to clear the virus.
It has been demonstrated previously that ribavirin is beneficial against cowpox virus infections in mice, particularly when the infecting virus challenge dose is not too Antiviral Chemistry & Chemotherapy 12:6 7 severe (Smee et al., 2000a) . The drug was beneficial when combined with immune globulin against a vaccinia virus infection in a human patient (Kesson et al., 1997) . The data in Table 1 showed that ribavirin has some selectivity in preferentially inhibiting orthopoxviruses compared to its cell-inhibitory activity. The multiple modes of action of ribavirin combined with its low immunosuppressive effects ( Jolley & Hinshaw, 1980) may account for its ability to show efficacy against orthopoxvirus infections in animals and man.
